Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1050352

Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile


Vrkić Kirhmajer, Majda; Macolić Šarinić, Viola; Šimičević, Livija; Ladić, Iva; Putarek, Krešimir; Banfić, Ljiljana; Božina, Nada
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile // Basic & Clinical Pharmacology & Toxicology, 123 (2018), 4; 509-518 doi:10.1111/bcpt.13035 (međunarodna recenzija, prikaz, znanstveni)


CROSBI ID: 1050352 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile

Autori
Vrkić Kirhmajer, Majda ; Macolić Šarinić, Viola ; Šimičević, Livija ; Ladić, Iva ; Putarek, Krešimir ; Banfić, Ljiljana ; Božina, Nada

Izvornik
Basic & Clinical Pharmacology & Toxicology (1742-7835) 123 (2018), 4; 509-518

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, prikaz, znanstveni

Ključne riječi
DRUG-DRUG INTERACTIONS ; PHARMACOKINETIC INTERACTION ; HEALTHY-VOLUNTEERS ; 2017 ESC ; AMIODARONE ; POLYMORPHISMS ; SIMVASTATIN ; METABOLITES ; MANAGEMENT ; ELEVATION

Sažetak
Up to the beginning of 2018, a total of eight cases describing rare but clinically important drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis have been noted in the Global World Health Organization (WHO) adverse drug reaction (ADR) database (VigiBase) as well as in available literature. There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug- drug interactions (DDI) on metabolic enzymes (CYPs and UGTs) and drug transporter levels (ABCB1, ABCG2, OATP1B1) and pharmacogenetic predisposition. We reviewed all available cases plus the case of an 87-year-old female Croatian/Caucasian patient who developed rhabdomyolysis following concomitant treatment with rosuvastatin and ticagrelor. The results of the pharmacogenetic analysis indicated that the patient was a carrier of inactivating alleles CYP2C9*1/*3, CYP3A4*1/*22, CYP3A5*3/*3, CYP2D6*1/*4, UGT1A1*28/*28, UGT2B7 -161C/T, ABCB1 3435C/T and ABCB1 1237C/T which could have added to the interactions not only between ticagrelor and rosuvastatin but also other concomitantly prescribed medicines, such as amiodarone and proton pump inhibitors. In this case report, the possible multifactorial causes for rhabdomyolysis following concomitant use of rosuvastatin and ticagrelor such as old age, polypharmacy, renal impairment, along with pharmacogenetics will be discussed

Izvorni jezik
Engleski



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka

Poveznice na cjeloviti tekst rada:

doi onlinelibrary.wiley.com

Citiraj ovu publikaciju:

Vrkić Kirhmajer, Majda; Macolić Šarinić, Viola; Šimičević, Livija; Ladić, Iva; Putarek, Krešimir; Banfić, Ljiljana; Božina, Nada
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile // Basic & Clinical Pharmacology & Toxicology, 123 (2018), 4; 509-518 doi:10.1111/bcpt.13035 (međunarodna recenzija, prikaz, znanstveni)
Vrkić Kirhmajer, M., Macolić Šarinić, V., Šimičević, L., Ladić, I., Putarek, K., Banfić, L. & Božina, N. (2018) Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile. Basic & Clinical Pharmacology & Toxicology, 123 (4), 509-518 doi:10.1111/bcpt.13035.
@article{article, author = {Vrki\'{c} Kirhmajer, Majda and Macoli\'{c} \v{S}arini\'{c}, Viola and \v{S}imi\v{c}evi\'{c}, Livija and Ladi\'{c}, Iva and Putarek, Kre\v{s}imir and Banfi\'{c}, Ljiljana and Bo\v{z}ina, Nada}, year = {2018}, pages = {509-518}, DOI = {10.1111/bcpt.13035}, keywords = {DRUG-DRUG INTERACTIONS, PHARMACOKINETIC INTERACTION, HEALTHY-VOLUNTEERS, 2017 ESC, AMIODARONE, POLYMORPHISMS, SIMVASTATIN, METABOLITES, MANAGEMENT, ELEVATION}, journal = {Basic and Clinical Pharmacology and Toxicology}, doi = {10.1111/bcpt.13035}, volume = {123}, number = {4}, issn = {1742-7835}, title = {Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile}, keyword = {DRUG-DRUG INTERACTIONS, PHARMACOKINETIC INTERACTION, HEALTHY-VOLUNTEERS, 2017 ESC, AMIODARONE, POLYMORPHISMS, SIMVASTATIN, METABOLITES, MANAGEMENT, ELEVATION} }
@article{article, author = {Vrki\'{c} Kirhmajer, Majda and Macoli\'{c} \v{S}arini\'{c}, Viola and \v{S}imi\v{c}evi\'{c}, Livija and Ladi\'{c}, Iva and Putarek, Kre\v{s}imir and Banfi\'{c}, Ljiljana and Bo\v{z}ina, Nada}, year = {2018}, pages = {509-518}, DOI = {10.1111/bcpt.13035}, keywords = {DRUG-DRUG INTERACTIONS, PHARMACOKINETIC INTERACTION, HEALTHY-VOLUNTEERS, 2017 ESC, AMIODARONE, POLYMORPHISMS, SIMVASTATIN, METABOLITES, MANAGEMENT, ELEVATION}, journal = {Basic and Clinical Pharmacology and Toxicology}, doi = {10.1111/bcpt.13035}, volume = {123}, number = {4}, issn = {1742-7835}, title = {Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile}, keyword = {DRUG-DRUG INTERACTIONS, PHARMACOKINETIC INTERACTION, HEALTHY-VOLUNTEERS, 2017 ESC, AMIODARONE, POLYMORPHISMS, SIMVASTATIN, METABOLITES, MANAGEMENT, ELEVATION} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font